Reviewer's report

**Title:** Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report

**Version:** 1  **Date:** 23 April 2010

**Reviewer:** Atsuko Adachi

Which of the following best describes what type of case report this is?: Unreported or unusual side effects or adverse interactions involving medications

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: No

Is this case worth reporting?: Yes

Is the case report persuasive?: Yes

Does the case report have explanatory value?: Yes

Does the case report have diagnostic value?: Yes

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

**Comments to authors:**

1. I think you had better term 'interface dermatitis' instead of 'interphace dermatitis.' (p 4, & 5)

2. I think you had better use "within two weeks" instead of "in two weeks time." (p 5)

3. You should add the titer of anti SSA and SSB antibody 3~6 Months after stopping these chemotherapy. The patient might be subclinical Sjogren syndrome before starting chemotherapy.

**Quality of written English:** Needs some language corrections before being published